115 related articles for article (PubMed ID: 22186123)
1. Epidemiologic, clinical, and molecular characteristics of hereditary prostate cancer in Latvia.
Abele A; Vjaters E; Irmejs A; Trofimovičs G; Miklaševičs E; Gardovskis J
Medicina (Kaunas); 2011; 47(10):579-85. PubMed ID: 22186123
[TBL] [Abstract][Full Text] [Related]
2. An inherited NBN mutation is associated with poor prognosis prostate cancer.
Cybulski C; Wokołorczyk D; Kluźniak W; Jakubowska A; Górski B; Gronwald J; Huzarski T; Kashyap A; Byrski T; Dębniak T; Gołąb A; Gliniewicz B; Sikorski A; Switała J; Borkowski T; Borkowski A; Antczak A; Wojnar L; Przybyła J; Sosnowski M; Małkiewicz B; Zdrojowy R; Sikorska-Radek P; Matych J; Wilkosz J; Różański W; Kiś J; Bar K; Bryniarski P; Paradysz A; Jersak K; Niemirowicz J; Słupski P; Jarzemski P; Skrzypczyk M; Dobruch J; Domagała P; Narod SA; Lubiński J;
Br J Cancer; 2013 Feb; 108(2):461-8. PubMed ID: 23149842
[TBL] [Abstract][Full Text] [Related]
3. Founder mutations in early-onset, familial and bilateral breast cancer patients from Russia.
Sokolenko AP; Rozanov ME; Mitiushkina NV; Sherina NY; Iyevleva AG; Chekmariova EV; Buslov KG; Shilov ES; Togo AV; Bit-Sava EM; Voskresenskiy DA; Chagunava OL; Devilee P; Cornelisse C; Semiglazov VF; Imyanitov EN
Fam Cancer; 2007; 6(3):281-6. PubMed ID: 17333477
[TBL] [Abstract][Full Text] [Related]
4. BRCA1 gene-related hereditary susceptibility to breast and ovarian cancer in Latvia.
Tihomirova L; Vaivade I; Fokina O; Peculis R; Mandrika I; Sinicka O; Stengrevics A; Krilova A; Keire G; Petrevics J; Eglitis J; Timofejevs M; Leja M
Adv Med Sci; 2014 Mar; 59(1):114-9. PubMed ID: 24797986
[TBL] [Abstract][Full Text] [Related]
5. BRCA1 mutations and prostate cancer in Poland.
Cybulski C; Górski B; Gronwald J; Huzarski T; Byrski T; Debniak T; Jakubowska A; Wokołorczyk D; Gliniewicz B; Sikorski A; Stawicka M; Godlewski D; Kwias Z; Antczak A; Krajka K; Lauer W; Sosnowski M; Sikorska-Radek P; Bar K; Klijer R; Romuald Z; Małkiewicz B; Borkowski A; Borkowski T; Szwiec M; Posmyk M; Narod SA; Lubiński J
Eur J Cancer Prev; 2008 Feb; 17(1):62-6. PubMed ID: 18090912
[TBL] [Abstract][Full Text] [Related]
6. Founder mutations in BRCA1/2 are not frequent in Canadian Ashkenazi Jewish men with prostate cancer.
Hamel N; Kotar K; Foulkes WD
BMC Med Genet; 2003 Aug; 4():7. PubMed ID: 12911837
[TBL] [Abstract][Full Text] [Related]
7. Genotype-phenotype correlations among BRCA1 4153delA and 5382insC mutation carriers from Latvia.
Plakhins G; Irmejs A; Gardovskis A; Subatniece S; Rozite S; Bitina M; Keire G; Purkalne G; Teibe U; Trofimovics G; Miklasevics E; Gardovskis J
BMC Med Genet; 2011 Oct; 12():147. PubMed ID: 22032251
[TBL] [Abstract][Full Text] [Related]
8. Role of the Nijmegen breakage syndrome 1 gene in familial and sporadic prostate cancer.
Hebbring SJ; Fredriksson H; White KA; Maier C; Ewing C; McDonnell SK; Jacobsen SJ; Cerhan J; Schaid DJ; Ikonen T; Autio V; Tammela TL; Herkommer K; Paiss T; Vogel W; Gielzak M; Sauvageot J; Schleutker J; Cooney KA; Isaacs W; Thibodeau SN
Cancer Epidemiol Biomarkers Prev; 2006 May; 15(5):935-8. PubMed ID: 16702373
[TBL] [Abstract][Full Text] [Related]
9. High prevalence of two BRCA1 mutations, 4154delA and 5382insC, in Latvia.
Tikhomirova L; Sinicka O; Smite D; Eglitis J; Hodgson SV; Stengrevics A
Fam Cancer; 2005; 4(2):77-84. PubMed ID: 15951956
[TBL] [Abstract][Full Text] [Related]
10. Mutations predisposing to breast cancer in 12 candidate genes in breast cancer patients from Poland.
Cybulski C; Lubiński J; Wokołorczyk D; Kuźniak W; Kashyap A; Sopik V; Huzarski T; Gronwald J; Byrski T; Szwiec M; Jakubowska A; Górski B; Dębniak T; Narod SA; Akbari MR
Clin Genet; 2015 Oct; 88(4):366-70. PubMed ID: 25330149
[TBL] [Abstract][Full Text] [Related]
11. Clinical, molecular and geographical features of hereditary breast/ovarian cancer in latvia.
Gardovskis A; Irmejs A; Miklasevics E; Borosenko V; Bitina M; Melbarde-Gorkusa I; Vanags A; Kurzawski G; Suchy J; Górski B; Gardovskis J
Hered Cancer Clin Pract; 2005 Apr; 3(2):71-6. PubMed ID: 20223033
[TBL] [Abstract][Full Text] [Related]
12. Strong founder effects in BRCA1 mutation carrier breast cancer patients from Latvia. Mutation in brief no. 258. Online.
Csokay B; Tihomirova L; Stengrevics A; Sinicka O; Olah E
Hum Mutat; 1999; 14(1):92. PubMed ID: 10447273
[TBL] [Abstract][Full Text] [Related]
13. BRCA1 mutations do not increase prostate cancer risk: results from a meta-analysis including new data.
Fachal L; Gómez-Caamaño A; Celeiro-Muñoz C; Peleteiro P; Blanco A; Carballo A; Forteza J; Carracedo A; Vega A
Prostate; 2011 Dec; 71(16):1768-79. PubMed ID: 21520156
[TBL] [Abstract][Full Text] [Related]
14. NBS1 is a prostate cancer susceptibility gene.
Cybulski C; Górski B; Debniak T; Gliniewicz B; Mierzejewski M; Masojć B; Jakubowska A; Matyjasik J; Złowocka E; Sikorski A; Narod SA; Lubiński J
Cancer Res; 2004 Feb; 64(4):1215-9. PubMed ID: 14973119
[TBL] [Abstract][Full Text] [Related]
15. Ashkenazi founder BRCA1/BRCA2 mutations in Slovak hereditary breast and/or ovarian cancer families.
Cierniková S; Tomka M; Kovác M; Stevurková V; Zajac V
Neoplasma; 2006; 53(2):97-102. PubMed ID: 16575464
[TBL] [Abstract][Full Text] [Related]
16. Nationwide study of clinical and molecular features of hereditary non-polyposis colorectal cancer (HNPCC) in Latvia.
Irmejs A; Borosenko V; Melbarde-Gorkusa I; Gardovskis A; Bitina M; Kurzawski G; Suchy J; Gorski B; Gardovskis J
Anticancer Res; 2007; 27(1B):653-8. PubMed ID: 17348456
[TBL] [Abstract][Full Text] [Related]
17. High frequency and allele-specific differences of BRCA1 founder mutations in breast cancer and ovarian cancer patients from Belarus.
Bogdanova NV; Antonenkova NN; Rogov YI; Karstens JH; Hillemanns P; Dörk T
Clin Genet; 2010 Oct; 78(4):364-72. PubMed ID: 20569256
[TBL] [Abstract][Full Text] [Related]
18. BRCA1 5382insC founder mutation has not a significative recurrent presence in Northeastern Romanian cancer patients.
Negură L; Duşa CP; Balmuş MI; Azoicăi D; Negură AM; Marinca MV; Miron L
Rom J Morphol Embryol; 2015; 56(2):379-85. PubMed ID: 26193202
[TBL] [Abstract][Full Text] [Related]
19. The contribution of founder mutations to early-onset breast cancer in French-Canadian women.
Ghadirian P; Robidoux A; Zhang P; Royer R; Akbari M; Zhang S; Fafard E; Costa M; Martin G; Potvin C; Patocskai E; Larouche N; Younan R; Nassif E; Giroux S; Narod SA; Rousseau F; Foulkes WD
Clin Genet; 2009 Nov; 76(5):421-6. PubMed ID: 19863560
[TBL] [Abstract][Full Text] [Related]
20. Do founder mutations characteristic of some cancer sites also predispose to pancreatic cancer?
Lener MR; Scott RJ; Kluźniak W; Baszuk P; Cybulski C; Wiechowska-Kozłowska A; Huzarski T; Byrski T; Kładny J; Pietrzak S; Soluch A; Jakubowska A; Lubiński J
Int J Cancer; 2016 Aug; 139(3):601-6. PubMed ID: 27038244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
